[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals (ALNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 30,590,078
  • Shares Outstanding, K 133,809
  • Annual Sales, $ 3,714 M
  • Annual Income, $ 313,750 K
  • EBIT $ 1,000 M
  • EBITDA $ 1,055 M
  • 60-Month Beta 0.30
  • Price/Sales 8.09
  • Price/Cash Flow 80.33
  • Price/Book 22.19

Options Overview Details

View History
  • Implied Volatility 43.71% (+2.91%)
  • Historical Volatility 105.31%
  • IV Percentile 39%
  • IV Rank 37.64%
  • IV High 59.29% on 07/27/26
  • IV Low 34.30% on 08/22/25
  • Expected Move (DTE 2) 6.12 (2.56%)
  • Put/Call Vol Ratio 0.40
  • Today's Volume 992
  • Volume Avg (30-Day) 1,693
  • Put/Call OI Ratio 0.52
  • Today's Open Interest 45,940
  • Open Int (30-Day) 37,409
  • Expected Range 233.39 to 245.63

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 28 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $1.68
  • Number of Estimates 9
  • High Estimate $2.87
  • Low Estimate $1.27
  • Prior Year $1.84
  • Growth Rate Est. (year over year) -8.70%

Price Performance

See More
Period Period Low Period High Performance
1-Month
197.81 +20.30%
on 07/30/26
290.60 -18.11%
on 07/29/26
-29.51 (-11.03%)
since 07/17/26
3-Month
197.81 +20.30%
on 07/30/26
380.00 -37.38%
on 07/09/26
-56.33 (-19.14%)
since 05/19/26
52-Week
197.81 +20.30%
on 07/30/26
495.55 -51.98%
on 10/20/25
-220.32 (-48.07%)
since 08/19/25

Most Recent Stories

More News
ALNY ALERT: Investigation Launched Into Alnylam Pharmaceuticals, Inc., Investors Are Encouraged to Contact KTMC Law Firm

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

ALNY : 237.06 (+3.70%)
ALNY Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

ALNY : 237.06 (+3.70%)
Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm

RADNOR, Pa. , Aug. 16, 2026 /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ), a nationally recognized securities litigation law firm, is investigating potential violations...

ALNY : 237.06 (+3.70%)
NASDAQ: ALNY Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm

Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Alnylam...

ALNY : 237.06 (+3.70%)
ALNY Investors Have Opportunity to Join Alnylam Pharmaceuticals, Inc. Fraud Investigation with SBS Law

LOS ANGELES , Aug. 4, 2026 /PRNewswire/ -- Schall, Brown & Schwartz  LLP ("SBS"), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors...

ALNY : 237.06 (+3.70%)
ALNY Investors Have Opportunity to Join Alnylam Pharmaceuticals, Inc. Fraud Investigation with SBS Law

Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. (“Alnylam”...

ALNY : 237.06 (+3.70%)
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

Glancy Prongay Wolke & Rotter LLP , a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Alnylam Pharmaceuticals, Inc. (“Alnylam”...

ALNY : 237.06 (+3.70%)
Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Law Offices of Howard G. Smith announces an investigation on behalf of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY ) investors concerning the Company’s...

ALNY : 237.06 (+3.70%)
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

The Law Offices of Frank R. Cruz announces an investigation of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY ) on behalf of investors concerning...

ALNY : 237.06 (+3.70%)
Alnylam: Q2 Earnings Snapshot

Alnylam: Q2 Earnings Snapshot

ALNY : 237.06 (+3.70%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Alnylam Pharmaceuticals Inc. is a development-stage biopharmaceutical company focused on the development of novel therapeutics based on RNA interference. The company's pipeline of experimental RNAi therapeutics is focused across three strategic therapeutic areas - genetic medicines, cardio-metabolic...

See More

Key Turning Points

3rd Resistance Point 241.24
2nd Resistance Point 236.08
1st Resistance Point 232.34
Last Price 237.06
1st Support Level 223.44
2nd Support Level 218.28
3rd Support Level 214.54

See More

52-Week High 495.55
Fibonacci 61.8% 381.81
Fibonacci 50% 346.68
Fibonacci 38.2% 311.55
Last Price 237.06
52-Week Low 197.81

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.